115 related articles for article (PubMed ID: 30449892)
41. Difference in killing activity of caspofungin and paradoxical growth between Candida albicans and C. krusei clinical isolates in different media.
Varga I; Sóczó G; Kardos G; Kemény-Beke A; Kelentey B; Márton I; Majoros L
J Chemother; 2009 Feb; 21(1):36-41. PubMed ID: 19297270
[TBL] [Abstract][Full Text] [Related]
42. Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on continuous venovenous haemodiafiltration.
Pérez-Pitarch A; Ferriols-Lisart R; Aguilar G; Ezquer-Garín C; Belda FJ; Guglieri-López B
Int J Antimicrob Agents; 2018 Jan; 51(1):115-121. PubMed ID: 28666752
[TBL] [Abstract][Full Text] [Related]
43. Susceptibility of Candida albicans biofilms to caspofungin and anidulafungin is not affected by metabolic activity or biomass production.
Marcos-Zambrano LJ; Escribano P; Bouza E; Guinea J
Med Mycol; 2016 Feb; 54(2):155-61. PubMed ID: 26543157
[TBL] [Abstract][Full Text] [Related]
44. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin.
Stevens DA; Ichinomiya M; Koshi Y; Horiuchi H
Antimicrob Agents Chemother; 2006 Sep; 50(9):3160-1. PubMed ID: 16940118
[TBL] [Abstract][Full Text] [Related]
45. In vitro activity of caspofungin against planktonic and sessile Candida sp. cells.
Serefko A; Chudzik B; Malm A
Pol J Microbiol; 2006; 55(2):133-7. PubMed ID: 17419291
[TBL] [Abstract][Full Text] [Related]
46. In vitro Synergistic Activity of Caspofungin Plus Polymyxin B Against Fluconazole-Resistant Candida glabrata.
Adams EK; Ashcraft DS; Pankey GA
Am J Med Sci; 2016 Mar; 351(3):265-70. PubMed ID: 26992255
[TBL] [Abstract][Full Text] [Related]
47. Activity of exogenous tyrosol in combination with caspofungin and micafungin against Candida parapsilosis sessile cells.
Kovács R; Tóth Z; Nagy F; Daróczi L; Bozó A; Majoros L
J Appl Microbiol; 2017 Jun; 122(6):1529-1536. PubMed ID: 28321957
[TBL] [Abstract][Full Text] [Related]
48. Biofilms Formed by Isolates from Recurrent Vulvovaginal Candidiasis Patients Are Heterogeneous and Insensitive to Fluconazole.
Sherry L; Kean R; McKloud E; O'Donnell LE; Metcalfe R; Jones BL; Ramage G
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696240
[TBL] [Abstract][Full Text] [Related]
49. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.
Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2006 Oct; 44(10):3533-8. PubMed ID: 17021079
[TBL] [Abstract][Full Text] [Related]
50. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
[TBL] [Abstract][Full Text] [Related]
51. Pharmacodynamic and Immunomodulatory Effects of Micafungin on Host Responses against Biofilms of Candida parapsilosis in Comparison to Those of Candida albicans.
Simitsopoulou M; Chlichlia K; Kyrpitzi D; Walsh TJ; Roilides E
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866877
[TBL] [Abstract][Full Text] [Related]
52. Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey.
Dagi HT; Findik D; Senkeles C; Arslan U
Ann Clin Microbiol Antimicrob; 2016 May; 15(1):36. PubMed ID: 27245756
[TBL] [Abstract][Full Text] [Related]
53. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.
Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC
J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027
[TBL] [Abstract][Full Text] [Related]
54. Antifungal susceptibility of yeast bloodstream isolates collected during a 10-year period in Austria.
Beyer R; Spettel K; Zeller I; Lass-Flörl C; Achleitner D; Krause R; Apfalter P; Buzina W; Strauss J; Gregori C; Schüller C; Willinger B
Mycoses; 2019 Apr; 62(4):357-367. PubMed ID: 30636016
[TBL] [Abstract][Full Text] [Related]
55. In vitro effectiveness of anidulafungin against Candida sp. biofilms.
Rosato A; Piarulli M; Schiavone BP; Catalano A; Carocci A; Carrieri A; Carone A; Caggiano G; Franchini C; Corbo F; Montagna MT
J Antibiot (Tokyo); 2013 Dec; 66(12):701-4. PubMed ID: 24022607
[TBL] [Abstract][Full Text] [Related]
56. Antifungal susceptibilities, in vitro production of virulence factors and activities of ceragenins against Candida spp. isolated from vulvovaginal candidiasis.
Hacioglu M; Guzel CB; Savage PB; Tan ASB
Med Mycol; 2019 Apr; 57(3):291-299. PubMed ID: 29846682
[TBL] [Abstract][Full Text] [Related]
57. Measurement of voriconazole activity against Candida albicans, C. glabrata, and C. parapsilosis isolates using time-kill methods validated by high-performance liquid chromatography.
Li Y; Nguyen MH; Derendorf H; Cheng S; Clancy CJ
Antimicrob Agents Chemother; 2007 Aug; 51(8):2985-7. PubMed ID: 17517840
[TBL] [Abstract][Full Text] [Related]
58. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations.
Stevens DA; Espiritu M; Parmar R
Antimicrob Agents Chemother; 2004 Sep; 48(9):3407-11. PubMed ID: 15328104
[TBL] [Abstract][Full Text] [Related]
59. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.
Ghannoum MA; Chen A; Buhari M; Chandra J; Mukherjee PK; Baxa D; Golembieski A; Vazquez JA
Clin Microbiol Infect; 2009 Mar; 15(3):274-9. PubMed ID: 19210699
[TBL] [Abstract][Full Text] [Related]
60. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome.
Kartsonis N; Killar J; Mixson L; Hoe CM; Sable C; Bartizal K; Motyl M
Antimicrob Agents Chemother; 2005 Sep; 49(9):3616-23. PubMed ID: 16127030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
